Houston digital health startup acquired by Illinois-based company

M&A moves

Houston-based Melax Tech has been acquired. Photo via MelaxTech.com

A Houston startup has exited to a clinical terminology management and data quality solutions company.

Melax Technologies Inc., an artificial intelligence and natural language processing technology company, has been acquired by Intelligent Medical Objects, which is headquartered in the Chicago area. It's the first acquisition for IMO, and the deal will allow for the company to expand its offerings to various segments in the health care market.

"Today marks an exciting moment for IMO as we complete our first acquisition,” says Ann Barnes, CEO at IMO, in a news release. “Combining Melax Tech’s analytics and NLP capabilities with IMO’s clinical terminology and data quality platform will enable healthcare organizations to have a more comprehensive solution for both clinical operation and research.

"The acquisition will also help extend our state-of-the-art capabilities to payer, pharmaceutical, and life science companies,” she continues.

Founded in 2017 and based out of the Texas Medical Center Innovation Factory, Melax Tech is used by over 650 organizations for clinical trials optimization and more.

“We are thrilled to join forces with IMO and combine our NLP expertise with their clinical terminology and knowledge management solutions,” says Andre Pontin, CEO of Melax Tech, in the release. “Together, we will be able to offer healthcare organizations a powerful suite of solutions that will enable them to improve patient outcomes and reduce costs.”

Melax Tech has entered into a handful of strategic partnerships over its six-year existence and raised $600,000 in grant funding from the National Institute of Health and National Institute of Allergy and Infectious Diseases.

The details of the acquisition transaction have not been disclosed.

From Your Site Articles
Houston-based Melax Tech has developed multiple Natural language processing tools that are used by more than 650 health care and life science organizations. Photo via MelaxTech.com

Houston-based language processing co. lands latest partnership with UC Irvine

teamwork

Melax Tech Partners, a leader in natural language technology processing, announced a new partnership with the University of California at Irvine that will help researchers derive insights from the UCI Health Data Science Platform’s electronic health records system and improve patient care.

Melax will implement its signature text annotation tool LANN to pull information from clinical notes, and its CLAMP product to develop natural language processing customizations through the use of AI, according to a statement from the company.

“There has been a strong desire among UCI researchers to have the capability to analyze free-text clinical narrative data using cutting-edge NLP technologies," Kai Zheng, chief research information officer at UCI Health Affairs, says in a statement. "We are delighted to have this opportunity to work with Melax Tech to deploy their AI-driven annotation and analytics tools to help our researchers advance their research agenda by leveraging the vast amount of free-text data that our health system has accumulated in the past two decades.”

Natural language processing, or NLP, allows organizations and healthcare groups to sift through and analyze massive amounts of data at a rapid rate through the use of machine learning and AI. Houston-based Melax Tech, founded in 2017, has developed multiple NLP tools that are used by more than 650 health care and life science organizations, according to its website.

In addition to the recent partnership with UC Irvine, Melax has also recently partnered with Vanderbilt University Medical Center and the University of Western Pennsylvania on similar clinical projects.

Melax has also used its platforms to pull vital information from datasets relating to COVID-19, in both medical and social settings.

In March 2022, it was awarded a Phase 1 NIH Award, valued at $300,000, to develop informatics tools based on COVID-19 datasets with the San Diego Supercomputer Center at UC San Diego. The tool aims to help researchers better understand vast amounts of virus-related data and connect findings with other similar results.

In August, Melax also received another $300,000 grant from the National Institute of Allergy and Infectious Diseases to develop NLP-based algorithms that will "model, extract and synthesize vaccine misinformation from multiple popular social media sources," according to a statement. Melax will also develop a visualization that presents its findings on the misinformation into a compressible format.

"This is a very real topic affecting culture at present," Andre Pontin, CEO at Melax Tech, says in a statement. "And shows that we as a collective business and group of experts continue to be on the cutting-edge of science in the NLP and AI domain."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston VC funding nears $1B in first half of 2026, report says

by the numbers

Despite a weak second quarter, venture capital funding for Houston-area startups approached $1 billion in the first half of 2026, the region’s highest first-half total since 2022, according to the latest PitchBook-NVCA Venture Monitor.

This year’s first-half total of $962.4 million represented a nearly 8 percent increase over last year’s first-half total of $891.7 million. Dating back to 2016, this year’s first-half haul lags behind only 2021 and 2022 for the most first-half funding.

Houston’s year-over-year VC jump of 73 percent in the first quarter of 2026 more than made up for the year-over-year drop of 34 percent in the second quarter of 2026, according to the report.

Deal count tells a more encouraging story: Houston startups closed 102 deals in the first half, up from 93 a year earlier and the region’s busiest first half since 2022. However, the average deal size shrank, as no single funding source dominated the total.

Keep in mind that PitchBook and NVCA routinely revise quarterly numbers upward to reflect deals that were reported after a previous quarter’s data was published. So, in the case of Houston, numbers initially reported for the first quarter of 2026 may not match newly reported numbers.

Perhaps the most notable Houston-area deal announced in the first half of this year was Cart.com’s $180 million growth equity investment, led by Springcoast Partners. Cart.com is an e-commerce platform and logistics provider.

PitchBook-NVCA data shows Houston’s VC activity is growing modestly, delivering better numbers in the first half of 2026 versus 2024 and 2025, but it still sits below the highs of 2021 and 2022. This is one sign that so far in 2026, the national VC boom isn’t benefiting non-hub markets like Houston the way it’s boosting some hub markets, especially Silicon Valley and New York City.

Nationwide, AI dominated VC funding in the first half of this year. The sector made up 86 percent of VC from January through June. The report notes that the markets have still struggled to unlock IPOs, with SpaceX being the biggest exception, and few M&A deals outside health care have been significant.

14 climatech startups join Greentown Houston in first half of 2026

green team

Climatech incubator Greentown Labs reports that 14 startups have joined its Houston community so far this year.

The companies are among 30 new startups to have joined Greentown Houston and Greentown Boston in 2026. Four of the companies are headquartered in Houston.

The startups are working on a range of "hydrogen-powered heavy-duty transport to AI-driven grid interconnection," according to Greentown.

The local startups that joined Greentown Houston include:

  • Houston-based Focis AI, which transforms industrial laser scans into structured asset intelligence to automatically identify, classify and map components in refineries and plants
  • Houston-based Iron Lattice, which develops next-generation memory technology for AI and high-performance computing that improves energy efficiency, endurance and scalability while remaining compatible with existing semiconductor manufacturing
  • Houston-based Orbital Arc, which is developing a new ion engine designed to improve the efficiency and scalability of spacecraft propulsion from low Earth orbit to deep space
  • Houston-based Sustain Energy LLC, which delivers cleaner, lower-cost fuel to industrial customers in pipeline-absent, underserved markets, cutting their energy costs and emissions with no infrastructure investment on their end

Other startups from around the world joined the Houston incubator in the same time period, including:

  • Ankara-based AIS Field, which develops robotic, AI-assisted non-destructive inspection systems, including submersible tank and boiler crawlers
  • San Francisco-based Armada AI, which builds rapidly deployable modular and edge data centers that run on local, stranded, or renewable power
  • San Francisco-based Armeta, which turns complex engineering drawings and legacy documentation into structured, usable data
  • Pittsburgh-based Atlas Robotics, which develops a Physical AI platform that powers autonomous material-handling robots and AI-guided forklifts
  • Ghana-based Cocoa Potash, which transforms high-emissions agricultural waste from cocoa, coconut, and palm-nut into organic potash, fertilizer and renewable energy
  • Israel-based Criaterra, which produces low-carbon, cement-free building materials
  • Italy-based ETAK, which manufactures modular reactors that convert solid waste into clean syngas
  • Kenya-based FelixFusion, which uses its Felix platform to model every grid connection point, including capacity, upgrade costs, and constraints
  • San Diego-based Gemini Energy, which builds next-generation fuel cells for data-center power
  • Tokyo-based Hibot, which develops robotic systems for inspecting and maintaining infrastructure in hazardous, hard-to-access environments
  • Austin-based Sheetak, which designs and manufactures thermoelectric coolers, generators, and assemblies for solid-state cooling and energy harvesting
  • The Netherlands-based ToPerform, which makes AI-powered, non-intrusive fouling sensors that monitor pipelines around the clock and predict the optimal cleaning time

Another 16 startups joined Greentown's Boston incubator. See the full list of new members here.

More than 100 startups joined Greentown last year, according to an end-of-year reflection shared by Greentown CEO Georgina Campbell Flatter. Read more about them here.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

$12M pharmaceutical manufacturing facility to be built in Sugar Land

coming soon

A nearly $12 million drug manufacturing facility is coming to Sugar Land.

City leaders in Sugar Land recently approved a $1.3 million performance-based incentive for DeliverIt Group, a Sugar Land-based provider of specialty pharmacy, infusion therapy and clinical care services, for the development of the 60,000-square-foot facility.

The facility, which will be registered with the U.S. Food and Drug Administration (FDA), will compound medication. The process of drug compounding combines, mixes or alters ingredients to create a medication tailored to a certain patient. A compounded drug is created when an FDA-approved drug can’t meet a patient’s needs.

The facility, which will employ 55 people, will expand DeliverIt’s offerings from specialty pharmacy and infusion services to advanced pharmaceutical manufacturing. In a press release, the City of Sugar Land says the facility reinforces the suburb’s status as a hub for life sciences and health care innovation.

DeliverIt, founded in 2010, already employs about 60 people.

The $1.3 million incentive, to be distributed over the course of 10 years, is being funded through the Sugar Land Development Corporation’s 4A sales tax program.

“The addition of a pharmaceutical manufacturing operation of this caliber reflects the type of targeted growth we want to see in Sugar Land,” Jennifer Alexander, business development manager for the City of Sugar Land, said in a news release. “Our focus on smart, strategic investment means supporting life sciences innovators in ways that maximize existing assets while driving long-term community prosperity.”

The current size of the U.S. drug-compounding market is estimated at $7.42 billion, and it’s projected to climb to $12.79 billion by 2035, according to Towards Healthcare Research and Consulting.

Drug compounding is gaining momentum due to increases in personalized medicine and personal treatment approaches, with growth being supported by aging populations and the rise of chronic illnesses, Towards Healthcare says.

View All Listings